BioFrontier Partners, Inc.
Venture capitalTokyo · Series A–Late Stage · 11 people tracked
Find your way into BioFrontier Partners, Inc.
Investment thesis
BioFrontier Partners, Inc. is a Japan-based biotech-focused investment firm headquartered in Tokyo, with an additional presence in San Diego, USA.
Source: firm website, verified Jul 29, 2026.
Team · 11 people
from the firm's website & public directoriesFrequently asked questions
- What stage does BioFrontier Partners, Inc. invest at?
- BioFrontier Partners, Inc. invests at the Series A, Series B, Series C, Late Stage stages.
- What is BioFrontier Partners, Inc.'s typical check size?
- BioFrontier Partners, Inc. typically writes checks of $500K – $3M.
- What sectors does BioFrontier Partners, Inc. focus on?
- BioFrontier Partners, Inc. focuses on Biotech, Medical Devices.
- Where is BioFrontier Partners, Inc. located?
- BioFrontier Partners, Inc. is headquartered in Tokyo, JP.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.








.jpeg)